IGEN keeps up Origen court battle as Roche drops suit
This article was originally published in Clinica
IGEN International has said that it will maintain its Maryland court litigation against Roche Diagnostics over breaches of the licensing agreement for IGEN's proprietary Origen diagnostic detection technology. The company confirmed it was keeping up its action just as Roche agreed to dismiss its Delaware patent suit against IGEN, and agreed to reimburse IGEN's legal fees incurred in defending the suit. These amount to some $5.7 million.
You may also be interested in...
A patent-litigation settlement that Teva has reached with Ironwood and Allergan over Linzess will allow the Israeli firm to enter the US market with the linaclotide-based constipation treatment ahead of major rivals Mylan, Sandoz, Sun Pharma and Aurobindo.
Following Aspen’s admission last year that it was party to an illegal, anti-competitive agreement on fludrocortisone, Tiofarma has now also conceded to the UK’s Competition and Markets Authority that it took part in the deal.